USPTO issues three additional patents to strengthen Mersana’s ADC technologies
The US patent no. 8,808,679 provides coverage for anti-tumor payloads and customized linkers used in the company’s Dolaflexin conjugation platform. The second US patent no. 8,815,226 expands its
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.